Arch Therapeutics Introduces Experienced Directors and Executive Leadership

Arch Therapeutics Introduces Experienced Directors and Executive Leadership 
CAMBRIDGE, MA -- (Marketwired) -- 07/02/13 --   Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company
and developer of AC5(TM), a novel product aimed at controlling
bleeding and fluid loss in order to provide faster and safer surgical
and interventional care, is pleased to introduce Dr. Avtar Dhillon as
Board Chair, Dr. Arthur Rosenthal as Director, and Dr. Terrence W.
Norchi as President & CEO. 
Dr. Dhillon has served as the Chairman of our Board of Directors
since April 2013 and has been on the Board of Directors of Arch
Biosurgery, Inc. ("ABS") since May 2011. Previously, Dr. Dhillon was
the President and Chief Executive Officer of Inovio Pharmaceuticals,
Inc. (formerly Inovio Biomedical Corporation) from October 2001 to
June 2009, as President and Chairman of Inovio from June 2009 until
October 2009, as Executive Chairman until August 2011, and as
Chairman from September 2011. During his tenure at Inovio, Dr.
Dhillon led the successful turnaround of the company through a
restructuring, acquisition of technology from several European and
North American companies and a merger with VGX Pharmaceuticals to
develop a vertically integrated DNA vaccine development company with
one of the strongest development pipelines in the industry. Dr.
Dhillon led multiple successful financings for Inovio and concluded
several licensing deals that included global giants Merck and Wyeth
(now Pfizer). Prior to joining Inovio, Dr. Dhillon was vice president
of MDS Capital Corp. (now Lumira Capital Corp.), one of North
America's leading healthcare venture capital organizations. Dr.
Dhillon adds value to our Board of Directors with his extensive
experience as a member of boards of directors and senior management
of other public companies and with his experience in company
building, financing, and licensing with large industry partners.  
Dr. Rosenthal was appointed a director of the Company upon the
consummation of the Company's previously announced merger, and had
been the Chairman of the Board of ABS since April 2011. He has served
for 40 years in senior research and product development executive
roles for medical technology companies and in those roles has
successfully directed commercialization efforts for hundreds of novel
medical products. He was Chief Scientific Officer at Boston
Scientific from January 1994 to January 2005, Vice President of
Research and Development at Johnson and Johnson Medical Products,
Inc. from April 1990 to January 1994. Dr. Rosenthal is a valuable
member of our Board of Directors because of his high-ranking roles in
private and public medical device companies, his extensive experience
overseeing research and development and commercialization of a large
number of products in the medical field, and his company-building
acumen. Additional biographic information is available on the company
website or on the Company's Form 8-K with the SEC on June 26, 2013. 
Dr. Norchi commenced service as our President, Chief Executive
Officer and a director on the Company's Board of Directors on April
23, 2013. Dr. Norchi also served as the President, Chief Executive
Officer and director of ABS since co-founding it in 2006. Prior to
ABS, Dr. Norchi was a portfolio manager and pharmaceutical analyst at
Putnam Investments from April 2002 to September 2004. Prior to that,
he served as the senior global biotech and international
pharmaceutical equity analyst at Citigroup Asset Management from
January 2000 to March 2002, and as a sell-side analyst covering
non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York
City from September 1996 to December 1999. Dr. Norchi brings to our
Board of Directors invaluable experience and knowledge of our core
technology and proposed product candidates as a result of his
firsthand experience with the development of that technology, having
ushered it from the research laboratory to its current stage of
Additional biographic information is available on a Current Report on
Form 8-K filed with the SEC on June 26, 2013. Further details
regarding Arch Therapeutics, Inc. and its agreements are filed as
part of the Company's continuous public disclosure as a reporting
issuer under the Securities Exchange Act of 1934 filed with the
Securities and Exchange Commission ("SEC"), and are available at the
SEC's website at For more information, visit our website
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
(OTCQB: ARTH) is a medical device company developing a novel approach
to stop bleeding (hemostasis) and control leaking (sealant) during
surgery and trauma care. Arch's goal is to develop and commercialize
products based on our innovative technology platform that make
surgery and interventional care faster and safer for patients. Arch's
flagship development stage product candidate known as AC5(TM) is
being designed to elegantly achieve hemostasis in minimally invasive
and open surgical procedures. Find out more at  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans, our financial projections or market information. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among
others, the inherent uncertainties associated with developing new
products or technologies and operating as a development stage
company, our ability to raise the additional funding we will need to
continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, competition in the industry in which we operate and market
conditions. These forward-looking statements are made as of the date
of this news release, and we assume no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Although we believe that any beliefs, plans, expectations
and intentions contained in this press release are reasonable, there
can be no assurance that any such beliefs, plans, expectations or
intentions will prove to be accurate. Investors should consult all of
the information set forth herein and should also refer to the risk
factors disclosure outlined in the reports and other documents we
file with the SEC, available at 
On Behalf of the Board, 
Terrence W. Norchi, MD.
 Arch Therapeutics, Inc. 
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Press spacebar to pause and continue. Press esc to stop.